Cellular & regenerative
Preclinical
Peptide therapies
Widely marketed, thinly studied in humans, and in regulatory flux in the US.
How it works
These short amino-acid chains, such as BPC-157, TB-500, MOTs-c and epitalon, are proposed to act on tissue repair, mitochondrial signaling or other pathways, mostly based on animal and cell studies. They are distinct from FDA-approved peptide drugs such as GLP-1 medicines.
Hallmarks of aging targeted
Mitochondrial dysfunction · Altered intercellular communication
What the evidence says
Honest about what is proven, and what is not.
A PubMed search found no records indexed as clinical trials for BPC-157; most efficacy claims rest on preclinical data. On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted narrowly to recommend adding BPC-157, KPV, TB-500, MOTs-c, epitalon and Semax to the 503A bulk drug list. Those votes are advisory: as of late July 2026 the FDA had not finalized rulemaking. Learn more at YouthfulPeptide.com.
Key reference
McDermott Will & Schulte. PCAC backs majority of peptides in two-day public meeting. July 27, 2026
Considering this for yourself?
Many longevity therapies are experimental, off-label or not FDA-approved for aging. A physician-guided evaluation weighs your labs, history and goals before anything is started.
Explore other emerging therapeutics
Foundations
Exercise and resistance training
The best-evidenced healthspan intervention we have: aerobic fitness plus strength.
Foundations
Sleep, nutrition and caloric restriction
Daily inputs that shape metabolic aging; the strongest data are for caloric restriction.
Metabolic
GLP-1 receptor agonists
Obesity and diabetes drugs with proven heart benefits and an open question on aging.